Search research articles
Contact Us
Filters
Showing results (91-100 of 112) with videos related to
Page
of 12
Sort By:
The Journal of Clinical Endocrinology and Metabolism
|
September 13, 2003
Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts
Volker Viereck, Carsten Gründker, Sabine Blaschke, et al.
Gynecologic Oncology
|
April 10, 2014
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5)
Günter Emons, Grigor Gorchev, Jalid Sehouli, et al.
International Journal of Oncology
|
August 28, 2012
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells
Martin Block, Carsten Gründker, Stefanie Fister, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 20, 2005
Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts
Volker Viereck, Carsten Gründker, Stephanie C Friess, et al.
Gynecologic Oncology
|
September 19, 2003
Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer
Claire F Verschraegen, Silke Westphalen, Wei Hu, et al.
Gynecologic Oncology
|
March 19, 2013
Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie
Günter Emons, Andreas Günthert, Falk C Thiel, et al.
Pathophysiology of Haemostasis and Thrombosis
|
June 2, 2004
Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A and polymorphisms of plasminogen activator and plasminogen activator inhibitor
Cornelia E Wolf, Hannelore Haubelt, Hans Ulrich Pauer, et al.
Gynecologic Oncology
|
September 11, 2010
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors
Günter Emons, Manfred Kaufmann, Grigor Gorchev, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 15, 2014
Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5)
Günter Emons, Grigor Gorchev, Philipp Harter, et al.
Gynecologic Oncology
|
May 23, 2013
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)
Benoit You, Olivier Colomban, Mark Heywood, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 112) with videos related to
Sort By:
Page
of 12
The Journal of Clinical Endocrinology and Metabolism
|
September 13, 2003
Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts
Volker Viereck, Carsten Gründker, Sabine Blaschke, et al.
Gynecologic Oncology
|
April 10, 2014
Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5)
Günter Emons, Grigor Gorchev, Jalid Sehouli, et al.
International Journal of Oncology
|
August 28, 2012
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells
Martin Block, Carsten Gründker, Stefanie Fister, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
October 20, 2005
Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts
Volker Viereck, Carsten Gründker, Stephanie C Friess, et al.
Gynecologic Oncology
|
September 19, 2003
Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer
Claire F Verschraegen, Silke Westphalen, Wei Hu, et al.
Gynecologic Oncology
|
March 19, 2013
Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie
Günter Emons, Andreas Günthert, Falk C Thiel, et al.
Pathophysiology of Haemostasis and Thrombosis
|
June 2, 2004
Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A and polymorphisms of plasminogen activator and plasminogen activator inhibitor
Cornelia E Wolf, Hannelore Haubelt, Hans Ulrich Pauer, et al.
Gynecologic Oncology
|
September 11, 2010
Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors
Günter Emons, Manfred Kaufmann, Grigor Gorchev, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 15, 2014
Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5)
Günter Emons, Grigor Gorchev, Philipp Harter, et al.
Gynecologic Oncology
|
May 23, 2013
The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study)
Benoit You, Olivier Colomban, Mark Heywood, et al.
Page
of 12